Cargando…
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
Antibody‐based therapy in acute myeloid leukemia (AML) has been marred by significant hematologic toxicity due to targeting of both hematopoietic stem and progenitor cells (HSPCs). Achieving greater success with therapeutic antibodies requires careful characterization of the potential target molecul...
Autores principales: | Abadir, Edward, Gasiorowski, Robin E., Lai, Kaitao, Kupresanin, Fiona, Romano, Adelina, Silveira, Pablo A., Lo, Tsun‐Ho, Fromm, Phillip D., Kennerson, Marina L., Iland, Harry J., Ho, P. Joy, Hogarth, P. Mark, Bradstock, Kenneth, Hart, Derek N.J., Clark, Georgina J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763785/ https://www.ncbi.nlm.nih.gov/pubmed/31338922 http://dx.doi.org/10.1002/1878-0261.12549 |
Ejemplares similares
-
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
por: Lo, Tsun-Ho, et al.
Publicado: (2019) -
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
por: Li, Ziduo, et al.
Publicado: (2018) -
Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis
por: Silveira, Pablo A., et al.
Publicado: (2022) -
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
por: Abadir, Edward, et al.
Publicado: (2020) -
Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
por: Dix, Caroline, et al.
Publicado: (2020)